UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): DECEMBER 28, 2006

                                HEMOBIOTECH, INC.
--------------------------------------------------------------------------------
               (Exact Name of Company as Specified in Its Charter)

                                    DELAWARE
--------------------------------------------------------------------------------
                   (State or Other Jurisdiction of Incorporation)

                 000-51334                          33-0995817
--------------------------------------------------------------------------------
   (Commission File Number)                    (IRS Employer Identification No.)

 14221 DALLAS PARKWAY, SUITE 1400
 DALLAS, TEXAS                                            75254
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)               (Zip Code)

                                 (214) 540-8411
--------------------------------------------------------------------------------
                (Company's Telephone Number, Including Area Code)

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

|_| Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------

<PAGE>


ITEM 8.01.        OTHER EVENTS

     On December  28,  2006,  HemoBioTech,  Inc.,  a Delaware  corporation  (the
"Company"),  issued a press  release  reviewing its  activities  during 2006 and
discussing  its global  strategies  for 2007.  The press  release  issued by the
Company  regarding  the  foregoing  is included as Exhibit  99.1 to this Current
Report on Form 8-K and is  incorporated  by reference in its entirety  into this
Item 8.01.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS

(d)      Exhibits.

99.1     Press Release of HemoBioTech, Inc., dated December 28, 2006.



<PAGE>
                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934,
the  Company  has duly  caused  this  report to be  signed on its  behalf by the
undersigned thereunto duly authorized.

                                   HEMOBIOTECH, INC.

Date: January 3, 2007              By: /s/ Mark Rosenblum

                                   Name: Mark Rosenblum
                                   Title: Chief Financial Officer and Secretary


<PAGE>

EXHIBIT INDEX
Exhibit No.      Description
-----------      -----------
99.1             Press Release issued by HemoBioTech, Inc. on December 28, 2006.
[{"type": "8-K", "sequence": "1", "filename": "f8k_pr12282006.txt", "secsgml_size_bytes": 3618}]
{"company-data": {"conformed-name": "HEMOBIOTECH INC", "cik": "0001301348", "assigned-sic": "2836", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51334", "film-number": "07500789"}, "business-address": {"street1": "14221 DALLAS PARKWAY", "street2": "SUITE 1500", "city": "DALLAS", "state": "TX", "zip": "75254", "phone": "214-540-8411"}, "mail-address": {"street1": "14221 DALLAS PARKWAY", "street2": "SUITE 1500", "city": "DALLAS", "state": "TX", "zip": "75254"}}
UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): DECEMBER 28, 2006

                                HEMOBIOTECH, INC.
--------------------------------------------------------------------------------
               (Exact Name of Company as Specified in Its Charter)

                                    DELAWARE
--------------------------------------------------------------------------------
                   (State or Other Jurisdiction of Incorporation)

                 000-51334                          33-0995817
--------------------------------------------------------------------------------
   (Commission File Number)                    (IRS Employer Identification No.)

 14221 DALLAS PARKWAY, SUITE 1400
 DALLAS, TEXAS                                            75254
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)               (Zip Code)

                                 (214) 540-8411
--------------------------------------------------------------------------------
                (Company's Telephone Number, Including Area Code)

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

|_| Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------
ITEM 8.01.        OTHER EVENTS

     On December  28,  2006,  HemoBioTech,  Inc.,  a Delaware  corporation  (the
"Company"),  issued a press  release  reviewing its  activities  during 2006 and
discussing  its global  strategies  for 2007.  The press  release  issued by the
Company  regarding  the  foregoing  is included as Exhibit  99.1 to this Current
Report on Form 8-K and is  incorporated  by reference in its entirety  into this
Item 8.01.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS

(d)      Exhibits.

99.1     Press Release of HemoBioTech, Inc., dated December 28, 2006.
SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934,
the  Company  has duly  caused  this  report to be  signed on its  behalf by the
undersigned thereunto duly authorized.

                                   HEMOBIOTECH, INC.

Date: January 3, 2007              By: /s/ Mark Rosenblum

                                   Name: Mark Rosenblum
                                   Title: Chief Financial Officer and Secretary
EXHIBIT INDEX
Exhibit No.      Description
-----------      -----------
99.1             Press Release issued by HemoBioTech, Inc. on December 28, 2006.